HAVRIX JUNIOR VACCINE 720 elisa units/0.5 ml

**Indications** **Havrix** is indicated for active immunisation against hepatitis A virus (HAV) infection in subjects at risk of exposure to HAV. **Havrix** will not prevent hepatitis infection caused by other agents such as hepatitis B virus, hepatitis C virus, hepatitis E virus or other pathogens known to infect the liver. In areas of low to intermediate prevalence of hepatitis A, immunisation with **Havrix** is particularly recommended in subjects who are, or will be, at increased risk of infection such as: Travellers. Persons travelling to areas where the prevalence of hepatitis A is high. These areas include Africa, Asia, the Mediterranean basin, the Middle East, Central and South America. Armed Forces. Armed Forces personnel who travel to higher endemicity areas or to areas where hygiene is poor have an increased risk of HAV infection. Active immunisation is indicated for these individuals. Persons for whom hepatitis A is an occupational hazard or for whom there is an increased risk of transmission. These include employees in day-care centres, nursing, medical and paramedical personnel in hospitals and institutions, especially gastroenterology and paediatric units, sewage workers, food handlers, among others. Persons at increased risk due to their sexual behaviour. Homosexuals, persons with multiple sexual partners. Haemophiliacs. Abusers of Injectable Drugs. Contacts of Infected Persons. Since virus shedding of infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. Persons who require protection as part of hepatitis A outbreak control or because of regionally elevated morbidity. Specific population groups known to have a higher incidence of hepatitis A. For example American Indians, Eskimos, recognised community-wide HAV epidemics. Subjects with chronic liver disease or who are at risk of developing chronic liver disease (e.g. Hepatitis B (HB) and Hepatitis C (HC) chronic carriers and alcohol abusers). In areas of intermediate to high prevalence of hepatitis A (e.g. Africa, Asia, the Mediterranean basin, the Middle East, Central and South America) susceptible individuals may be considered for active immunisation.

**Contraindications** **Havrix** should not be administered to subjects with known hypersensitivity to any component of the vaccine (see _Qualitative and quantitative composition_ and _List of excipients_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_), or to subjects having shown signs of hypersensitivity after previous administration of **Havrix**.

GLAXOSMITHKLINE PTE LTD

Package Inserts